A

Aclaris Therapeutics
D

ACRS

3.86500
USD
-0.47
(-10.74%)
Market Closed
Volume
60,286
EPS
-1
Div Yield
-
P/E
-7
Market Cap
276,080,591
OverviewSignalsIdeasNews
Related Instruments
    A
    ADCT
    -0.27000
    (-10.19%)
    2.38000 USD
    A
    AGEN
    -0.05000
    (-1.80%)
    2.72500 USD
    A
    ALXO
    -0.04500
    (-3.35%)
    1.30000 USD
    AMGN
    AMGN
    -12.22
    (-4.13%)
    294.4 USD
    A
    APPH
    0
    (0%)
    0.000000 USD
    A
    ASMB
    -0.750
    (-4.48%)
    16.000 USD
    A
    ATNX
    -0.34000
    (-19.65%)
    1.43000 USD
    B
    BCRX
    -0.41500
    (-5.57%)
    7.03500 USD
    B
    BGNE
    -4.220
    (-2.18%)
    189.320 USD
    BIIB
    BIIB
    -4.840
    (-2.94%)
    160.000 USD
    B
    BPMC
    -6.990
    (-7.31%)
    88.690 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.16 USD
    N
    NBRV
    0.04000
    (2.84%)
    1.45000 USD
    N
    NKTR
    -0.11000
    (-9.36%)
    1.06500 USD
    NVS
    NVS
    -0.350
    (-0.34%)
    104.29 USD
    P
    PTCT
    -3.110
    (-7.34%)
    39.270 USD
    T
    TBIO
    0
    (0%)
    0.000000 USD
    More
News

Title: Aclaris Therapeutics

Sector: Healthcare
Industry: Diagnostics & Research
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; andATI-1777.